<u>Title:</u> Real-World Type 2 Diabetes Second-Line Treatment Allocation Among Patients

Authors:

Jaysón Davidson[1,2] [ORCID 0000-0001-9066-9872]

Rohit Vashisht, Ph.D.[1,2] [ORCID 0000-0002-2938-7259]

Kendra Radtke, PharmD, Ph.D.[1]

Ayan Patel[2]

Suneil K. Koliwad, M.D., Ph.D.[3,4] [ORCID 0000-0002-7367-1054]

Atul J. Butte, M.D., Ph.D.[1,2] [ORCID 0000-0002-7433-2740]

1. Bakar Computational Health Sciences Institute, University of California San Francisco, San

Francisco, CA

2. Center for Data-driven Insights and Innovation, University of California Health, Oakland, CA

3. Diabetes Center, University of California San Francisco, San Francisco, CA

4. Department of Medicine, Division of Endocrinology & Metabolism, University of California

San Francisco, San Francisco, CA

Corresponding Author:

Atul J. Butte M.D., Ph.D.

Keywords: Type 2 diabetes, treatment decision-making, social determinants of health,

healthcare disparities, area deprivation index

Abstract:

Objective: This study aimed to evaluate the impact of socioeconomic disparities on the allocation of second-line treatments among patients with type 2 diabetes (T2D).

Materials and Methods: We conducted an observational study using real-world data from over 9 million patients across five University of California Health centers. The study included patients who initiated a second-line T2D medication after metformin, with hemoglobin A1c (HbA1c) measurements within ±7 days of treatment initiation from 2012 through September 2024. Multinomial regression models assessed the association between socioeconomic status and second-line treatment choices. Additionally, we used the GPT-4 large language model with a zero-shot learning approach to analyze 270 clinical notes from 105 UCSF patients. GPT-4 identified adverse social determinants of health (SDOH) across six domains: transportation, housing, relationships, patients with children, support, and employment.

Results: Among 15,090 patients (56.7% male, 43.3% female; mean age 59.3 years; mean HbA1c 8.91%), second-line treatments included sulfonylureas (SUs; n = 6,732), DPP4 inhibitors (n = 2,918), GLP-1 receptor agonists (n = 2,736), and SGLT2 inhibitors (n = 2,704). Patients from lower socioeconomic neighborhoods were more likely to receive SUs over other medications: DPP4i (OR = 0.96, [95% CI, 0.95-0.98]), GLP-1RA (OR = 0.94, [95% CI, 0.92-0.96]), SGLT2i (OR = 0.95, [95% CI, 0.93-0.97]). In UCSF clinical notes, we identified adverse SDOH including housing (n=8), transportation (n=1), relationships (n=22), employment (n=12), support (n=1), and patients with children (n=25).

Conclusions: Socioeconomic factors influence second-line T2D treatment choices. Addressing these disparities is essential to ensuring equitable access to advanced T2D therapies.

Introduction:

The annual prevalence of Type 2 diabetes (T2D) remains elevated, affecting approximately

11.3% of the U.S. population and 9.3% of individuals globally, including minority groups[1,2].

Present clinical treatment guidelines target achievement of glycated hemoglobin A1c (HbA1c)

levels below 7% for most adults[3,4,5]. Metformin (MF) remains the first-line of therapy, however,

newer second-line treatments are often needed when metformin alone fails to achieve glycemic

control[6-9]. Factors, particularly social determinants of health (SDOH), which are the conditions in

the environments where people are born, live, learn, play, worship, and age are known to impact

a range of health, functioning, and quality of life outcomes[9,10]. Specific SDOH[10] such as

neighborhood disadvantage and socioeconomic status, along with other adverse factors, have

been previously studied and shown to significantly impact diabetes management[11-14], medication

adherence[15], and behaviors such as physical activity and dietary patterns[16-23]. Real-World

characterization studies show wide-spread heterogeneity in the choice of second-line

treatments[24-26]. However, the knowledge about the possible influence of patient-level SDOH on

the allocation of second-line treatments among patients with T2D remains limited

We sought to systematically analyze the association between SDOH, specifically

socioeconomic status (SES) as estimated by mapping of home location to the Area Deprivation

Index (ADI)[27] and the allocation of second-line treatments among patients with T2D after MF

monotherapy. The study leveraged clinical data from electronic health records (EHRs) of over 9

million patients across five academic medical centers within the University of California Health

(UC Health) system.

Methods:

Data

Data for this study was extracted from the University of California (UC) Health System, which

includes 20 health professional schools (6 medical schools), 5 academic health centers (UC

San Francisco, UC Los Angeles, UC Davis, UC Irvine, and UC San Diego), and 12 hospitals. It

is the eighth largest non-profit health system in the United States by revenue and has built a

secure central data warehouse (UCHDW) for operational improvement, promotion of quality

patient care, and enabling the next generation of clinical research[28]. The repository currently

holds data securely on over 9 million patients seen since 2012. Every quarter, EHR data is

extracted from each site and transformed into vendor neutral Observational Medical Outcomes

Partnership (OMOP) common data model used widely across the United States and the

world29. De-identification of the data has been completed to enable clinical research projects,

under guidance from UC campus institutional review boards, privacy, and compliance.

Research use of UCHDW is considered non-human subject's research.

Study Population

UCHDW data was extracted from patients diagnosed with T2D and had a documented

prescription of second-line treatment in addition to existing MF therapy. Patients with T2D were

identified using ICD-10 diagnosis code E11.*, HbA1c lab measurements **(eMethods Supp. 2),**

and T2D related drug prescriptions for four second-line treatment classes (GLP-1RA, SGLT2i,

DPP4i, and SU) **(eMethods Supp. 1),** from EHRs spanning from year 2012 up to November

2023. To select the cohort of patients who received a second-line SU prescription, for example,

we excluded individuals who had a previous order of another second-line treatment prior to the

prescription for an SU and those with documented type 1 diabetes or an atypical form of

diabetes such as gestational diabetes. We also excluded patients who did not have an order for

MF before receiving an SU, and those who lacked T2D diagnosis code prior to receiving the

SU. We also required patients to have documented HbA1c measurements within (+7/-7d) of SU

treatment initiation (index date), where the index date was the first prescription of SU (**Figure-**

1). Finally, we excluded all patients whose HbA1c was < 6.5% and were under 17 years of age

at the time of SU treatment initiation and those who did not have an ADI value reported at the

index date. Similar exclusion and inclusion criteria were applied to select individuals with other

second-line T2D medications. This study followed the Strengthening the Reporting of

Observational Studies in Epidemiology (STROBE) reporting guidelines to ensure the quality of

our observational study[30].

Area Deprivation Index (ADI)

We utilized the ADI as a metric to estimate patient-level SDOH[27]. ADI serves as a valuable

resource for identifying and assessing healthcare needs for clinical treatments among patients

by providing a general estimate of SDOH based on home location census tract characteristics.

This index integrates SDOH data from 17 different census tract variables sourced from the U.S.

Census, with factors related to poverty, housing, employment, and education. ADI as a metric

has been used in previous observational studies[31-35] to understand its SDOH role on health

outcomes in other disease states. For this study, census tract-based SDOH data was

calculated to create the ADI, which ranks areas by percentiles, distinguishing the most deprived

areas with higher percentile scores from the least deprived areas with lower percentile

scores[27,36,37].

Study Variables

To describe patient baseline characteristics, we used ADI, HbA1c, Age (in years), patient

reported Sex (Male, Female), presence of primary insurance coverage, patient-reported Race,

and Ethnicity. T2D severity was inferred as the average of HbA1c measurements taken within

the (+7/-7d) window relative to the index date. Age (in years) was calculated relative to the

index date from date of birth. Patients with primary insurance healthcare coverage were utilized

as Medicare, Medicaid, or private insurance types. Patient reported race was categorized as

White, Asian, Black or African American category, Native Hawaiian or Pacific Islander,

American Indian or Alaska Native category, Multi-Race, Other Race, or Unknown. Patient

reported ethnicity was categorized as Hispanic or Latino, Not Hispanic or Latino or Unknown.

Statistical Analysis

Descriptive statistics were calculated first for each covariate and then for the overall patient

population. Multinomial regression was used to estimate the association of ADI with second-line

treatment allocation, adjusting for other covariates considered in this study[38,39]. For the

multinomial regression, the four second-line treatment classes (GLP-1RA, SGLT2i, DPP4i, and

SU) were considered as outcomes, with SU serving as the reference class. We adjusted for

HbA1c, age (in years), sex (Male, Female), primary insurance coverage, race, and ethnicity by

using a multinomial regression model [40,41]. Association and its strength was reported as odds

ratio with 95% confidence Intervals (CI) including p-values indicating the statistical significance

of how likely a patient was to receive a second-line treatment compared with SU when adjusted

for study covariates. An Odds Ratio (OR) was considered significant if it's 95% CI did not span

1, and p-value < 0.05. An OR = 1 indicates no difference between SU and other second-line

treatments, OR > 1 indicates an increased likelihood of allocating other second-line treatments

compared with SU, and OR < 1 indicates decreased likelihood of allocating other second-line

treatments compared with SU. All calculations were performed using R statistical software

version 3.6.3 (R Project for Statistical Computing).

SDOH Identification through Large Language Models

To identify individual-level SDOH factors, we extracted T2D patients from the UCSF

Deidentified clinical database using the inclusion and exclusion criteria outlined in the study

population section of the methods. We excluded patients who did not have clinical notes

associated with their diagnoses. Further, we excluded patients whose clinical notes did not

contain Social History or SDOH information, resulting in a final cohort of 105 patients with 270

clinical notes **(Supplement-3)**. To identify individual-level SDOH factors, we utilized the GPT-4

inference model with a zero-shot learning approach. GPT-4 was prompted to analyze the Social

History and SDOH sections of the clinical notes written by physicians. The model's accuracy

was first tested and validated using an annotated synthetic dataset and further evaluated with

an annotated MIMIC-III dataset curated by Guevara et al[42]. Outputs from these sample datasets

were compared against the ground truth to check for accuracy in identifying SDOH factors

(Supplement-3). GPT-4 was then prompted with the task to identify SDOH factors within UCSF

clinical notes, categorized into the following domains as outlined in the annotation guidelines by

Guevara et al.: Transportation (Distance, Resource, Other), Housing (Poor, Undomiciled,

Other), Relationship (Married, Partnered, Divorced, Widowed, Single), Parent, Support (Minus,

Plus), Employment (Employed, Underemployed, Unemployed, Disability, Retired, Student)[42].

Adverse SDOH factors were consolidated into broader categories: Adverse Transportation,

Adverse Housing, Adverse Relationship, Patients with Children, Adverse Support, and Adverse

Employment. The identified SDOH factors were visualized and plotted.

Results:

Our study included 15,090 patients (mean age 59.3 years, SD 13.4 years). **Table 1** presents a

summary of treatment allocation and demographic information. Of these patients, 6,732 were

prescribed SU, 2,704 were prescribed DPP4i, 2,918 were prescribed GLP-1RA, and 2,736 were

prescribed SGLT2i after final inclusion and exclusion criteria. 56.7% of the patients identified as

male, 43.3% female, and 46.6% identified as White. Primary Insurance coverage was distributed among patients as private (43.1%), medicaid (30.1%), medicare (25.0%), and veterans affairs (1.8%). The mean [SD] HbA1c values, reflecting T2D disease severity across second-line treatments, were: DPP4i (8.59% [1.85]), GLP-1RA (8.83% [2.06]), SGLT2i (8.62% [1.88]), and SU (9.19% [2.02]). Overall, the ADI for each second-line treatment allocation was skewed toward the least economically disadvantaged neighborhoods (ADI < 5), totaling 52.4% of patients in the study cohort. Older patients (OR = 1.02 [95% CI, 1.01-1.02]), as well those self-identifying as Asian (OR = 1.19, [95% CI, 1.05-1.35]), American Indian or Alaskan Native (OR = 1.33, [95% CI, 0.74-2.41]) were more likely to be prescribed a DPP4i as compared to individuals who identify as White (**Table 2**) adjusting for ADI. Females (OR = 1.44, [95% CI, 1.31-1.58]) were more likely to be prescribed GLP-1RA compared to Males. Patients who identified as Unknown Race (OR = 1.81, [95% CI, 1.49-2.20]) were more likely to be prescribed SGLT2i when compared to Whites. While patients identifying as "Other" race (OR = 1.21, [95% CI, 1.06-1.38]) were more likely to be prescribed DPP4i when compared to White patients. Hispanic patients were less likely to be prescribed DPP4i (OR = 0.73, [95% CI, 0.64-0.83]), GLP-1RA (OR = 0.78, [95% CI, 0.69-0.88]), and SGLT2i (OR = 0.90, [95% CI, 0.79-1.02]) when compared to non-Hispanic patients.

Our results also highlighted that HbA1c was a significant determinant of second-line treatment allocation, specifically preferring an order of SU after metformin initiation, aligning with known treatment guidelines[6]. With every unit increase in HbA1c percentage indicative of increased disease severity, patients were more likely to be prescribed an SU versus any of the other three second-line treatments DPP4i (OR = 0.90, [95% CI, 0.88-0.92]), GLP-1RA (OR = 0.90, [95% CI, 0.87-0.92]), SGLT2i (OR = 0.88, [95% CI, 0.85-0.90]). Additionally, our results highlighted that primary insurance coverage was significant in determining second-line treatment allocation. Patients with Medicaid as their primary insurance coverage were less likely to receive to GLP-1RA when compared to patients with private (OR = 2.39, [95% CI, 2.12-2.69]), medicare (OR = 1.30, [95% CI, 1.12-1.51]), or veterans affairs insurance (OR = 2.26, [95% CI, 1.60-3.21]).

Interestingly, we found ADI to be a significant independent variable underlying allocation of four second-line treatments. As ADI increased from a relatively low value reflecting a least economic

disadvantage to progressively higher values reflecting low socioeconomic neighborhoods,

patients were more likely to be prescribed an SU versus the other three second-line treatments

DPP4i (OR = 0.96, [95% CI, 0.95-0.98]), GLP-1RA (OR = 0.94, [95% CI, 0.92-0.96]), SGLT2i

(OR = 0.95, [95% CI, 0.93-0.97]). As illustrated with randomly selected patients that followed

the similar inclusion and exclusion criteria in our study but were not part of the model building

(**Figure-2**), a Hispanic female patient aged 46 years with an HbA1c of 11.8% and Private

insurance as their primary insurance living in a least disadvantaged neighborhood (ADI 1) is

most likely to be prescribed a GLP-1RA as a second-line medication in addition to MF (38.5%

likelihood). Whereas a non-Hispanic White male patient aged 49 years with an HbA1c of 11.9%

and Medicaid as their primary insurance who lives in a economically disadvantaged

neighborhood (ADI 10) is most likely to be prescribed SU as a second-line treatment (67.2%

likelihood). In another example, a Hispanic female patient aged 53 years with a 9.2% HbA1c

and Medicaid insurance living in ADI 10 is most likely to be prescribed SU as a second-line

treatment (61.0% likelihood).

Our results from prompt engineering using GPT-4 LLMs showed the identification of individual-

level SDOH factors for 105 patients whose clinical notes contained social history. Among UCSF

patients with clinical notes, 54 were prescribed SU, 21 were prescribed DPP4i, 15 were

prescribed GLP-1RA, and 15 were prescribed SGLT2i. We identified the following present

SDOH factors among these patients: adverse housing (n=8), adverse transportation (n=1),

adverse relationships (n=22), adverse employment (n=12), adverse support (n=1), and patients

with children (n=25) (**Figure-3**).

Discussion:

In this retrospective cohort study, we evaluated the association of social determinants of health

such as ADI on the allocation of second-line treatments among patients with T2D. We found

that as socioeconomic disadvantage metrics ranged from relatively affluent to progressively

socioeconomically disadvantaged neighborhoods, patients were more likely to receive an SU, a

less clinically effective, but more cost-effective treatment[3,6,8]. Conversely, patients who lived in

relatively least socioeconomic disadvantaged neighborhoods were more likely to receive newer,

more expensive, and potentially more effective second-line treatments such as SGLT2i, DPP4i,

and GLP-1RA. We also found that patients with Medicaid as their primary insurance, often
associated with low-cost healthcare coverage, were less likely to receive these advanced
second-line therapies. This disparity underlying treatment allocation is important, given that
SGLT2i and GLP-1RAs have clearly shown benefits in limiting development of serious
comorbid conditions including CKD, cardiovascular events, heart failure, and obesity[3,6]. Our
findings thus highlight a gap in the fair allocation of effective second-line treatments among
patients with T2D.
257
Beyond underlying socioeconomic disparities in second-line treatment allocation, we also found
a reliance favoring SU when the urgency for glucose lowering was highest. Indeed, in each
comparative analysis of specific agents as second-line treatments for T2D, we found that the
worse a patient's glycemic control, as measured by HbA1c, the more likely that patient was to
receive an SU. This reliance is in line with the traditional prescribing patterns and older ADA
guidelines that emphasize SU treatment as the first adjunct to MF for T2D. It also highlights the
notion that older more established medication classes might be favored when A1c lowering is
the top priority, regardless of SES. This fits with classic literature and ongoing supportive data
indicating that optimal HbA1c lowering remains the most important factor in limiting the
development of T2D-associated complications[6]. This finding is important because it highlights
that patients with a high ADI are more likely to have a more severe A1c at second-line
treatment initiation and are more likely to receive SU.
270
Our analysis also revealed disparities in second-line treatment allocation based on patient sex
and age. First, we found that males were more likely to receive a DPP4i, or a GLP-1RA over
SU compared to females, potentially consistent with the fact that adult males have higher T2D
rates than females[43]. Advancing age was associated with a higher likelihood of receiving an SU
over other second-line treatment choices. This finding may reflect a preference for SU among
aged patients to minimize risk of hypoglycemia, cognitive impairment, and autonomic symptoms
during management of diabetes[6].
278
Our study showed that patients prescribed SU as a second-line treatment had a higher
prevalence of documented adverse SDOH factors compared to those prescribed GLP-1RA,

SGLT2i, and DPP4i. More specifically, these patients faced challenges such as adverse

housing, relationships, transportation issues, with many also having caregiving responsibilities

for children. This suggests they may have been prescribed a cost-effective treatment rather

than a newer second-line option due to non-medical factors. Interestingly, patients prescribed

SGLT2i had a higher prevalence of documented adverse employment factors than those

prescribed other treatments, indicating that some patients facing employment challenges are

still being treated with newer drugs. However, the relatively low number of individual-level

SDOH factors captured in our data provides only a partial view of the adverse contributors

influencing a patient's second-line treatment prescription.

There are several limitations in the study. The health disparities associated with SES in the

UCHDW, as highlighted in our study, were estimated using the ADI at the neighborhood level,

which only provides an approximate measure of a patient's SES. Additionally, the inability to

capture a significant amount of individual-level SES data and other SDOH parameters due to

the absence of such data elements, limited a comprehensive evaluation of the patient

population. We acknowledge that our understanding of SES at the individual level remains

incomplete and could potentially be improved in future studies. The sample size of our data was

also constrained, primarily due to the stringent cohort selection criteria employed in this study.

Furthermore, our study does not account for the approval dates of newer drugs such as

SGLT2i, DPP4i, and GLP-1RA which were introduced later during the study period. Lastly, the

distribution of patients in this study was slightly skewed towards least economically

disadvantaged neighborhoods due to the high number of patients living in higher

socioeconomic areas that are treated within the UC-Health System.

Our findings serve as a preliminary step toward a deeper exploration of how individual SES and

SDOH can contribute to health disparities when data is collected in large quantities. We believe

that differences in disease severity at second-line treatment allocation may stem from factors

such as limited access to healthcare, financial constraints, low health literacy, and geographic

location of a patient. Moreover, our findings suggest that disparities in treatment allocation may

be influenced by treatment cost and unequal access to healthcare providers who prescribe

newer, more effective medications (e.g., GLP-1RA). To further understand the disparities

highlighted in our study, a comprehensive examination of high-quality individual-level SDOH factors is needed to effectively address the underlying issues pertaining to treatment selection and disease severity disparities.

In conclusion, our analysis highlights the association of SDOH with treatment choices, significantly impacting disease state and health outcomes. Our study shows growing associations of SDOH on clinical treatments, with and without adjusting for other covariates. Furthermore, our study shows that SDOH can be utilized to understand differences in care among patients from distinct population groups based on socioeconomic status. The recognition of SDOH disparities within the UC-Health system for T2D extends to healthcare systems across the United States. Understanding the role of SDOH, alongside considerations of disease severity, age, and sex, is crucial in addressing disparities in care among diverse population groups. A comprehensive understanding of treatment disparities will lead to the fair allocation of medical resources to population groups in which disparities exist. Most importantly utilizing SDOH to understand differences in care for multiple disease could drive institutions to improve their delivery of care to disparate population groups. Therefore, we must encourage the generation of high-quality SDOH data at both the neighborhood and individual level to increase the viability of clinical-related questions across disease states.

Author Contributions/Acknowledgements

Conceptualization, J.D., R.V., K.R and A.J.B.; writing—original draft preparation, J.D.; writing—review and editing, J.D., R.V., S.K.K, and A.J.B, Area Deprivation Index data, A.P. All authors have read and agreed to the published version of the manuscript.

Funding

Research reported in this publication was supported by the UCSF Bakar Computational Health Sciences Institute, and the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI grant number UL1 TR001872, along with the Food and Drug Administration, through U01 FD005978 to the UCSF–Stanford Center of Excellence in Regulatory Sciences and Innovation (CERSI). Its contents are solely the responsibility of the

authors and do not necessarily represent the official views of the NIH or FDA. None of the study

sponsors had any influence over the data interpretation or conclusions of this study.

Conflicts of Interest:

Kendra Radtke is a current employee and shareholder of Genentech/Roche. Atul Butte is a co-

founder and consultant to Personalis and NuMedii; consultant to Mango Tree Corporation, and

in the recent past, Samsung, 10x Genomics, Helix, Pathway Genomics, and Verinata (Illumina);

has served on paid advisory panels or boards for Geisinger Health, Regenstrief Institute,

Gerson Lehman Group, AlphaSights, Covance, Novartis, Genentech, Merck, and Roche; is a

shareholder in Personalis and NuMedii; is a minor shareholder in Apple, Meta (Facebook),

Alphabet (Google), Microsoft, Amazon, Snap, 10x Genomics, Illumina, Regeneron, Sanofi,

Pfizer, Royalty Pharma, Moderna, Sutro, Doximity, BioNtech, Invitae, Pacific Biosciences,

Editas Medicine, Nuna Health, Assay Depot, and Vet24seven, and several other non-health-

related companies and mutual funds; and has received honoraria and travel reimbursement for

invited talks from Johnson and Johnson, Roche, Genentech, Pfizer, Merck, Lilly, Takeda,

Varian, Mars, Siemens, Optum, Abbott, Celgene, AstraZeneca, AbbVie, Westat, and many

academic institutions, medical or disease-specific foundations and associations, and health

systems. Atul Butte receives royalty payments through Stanford University for several patents

and other disclosures licensed to NuMedii and Personalis. Atul Butte's research has been

funded by NIH, Peraton (as the prime on an NIH contract), Genentech, Johnson and Johnson,

FDA, Robert Wood Johnson Foundation, Leon Lowenstein Foundation, Intervalien Foundation,

Priscilla Chan and Mark Zuckerberg, the Barbara and Gerson Bakar Foundation, and in the

recent past, the March of Dimes, Juvenile Diabetes Research Foundation, California

Governor's Office of Planning and Research, California Institute for Regenerative Medicine,

L'Oreal, and Progenity.

References:

1. Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843. doi:10.1016/j.diabres.2019.107843

2. Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html. Accessed November 2023.

3. American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2020. Diabetes Care. 2020;43(Suppl 1):S66-S76. doi:10.2337/dc20-S006

4. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-1966. doi:10.1007/s00125-022-05787-2

5. International Diabetes Federation. Recommendations for managing type 2 diabetes in primary care. Accessed April 5, 2023. http://www.idf.org/managing-type2-diabetes

6. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125-S143. doi:10.2337/dc22-S009

7. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343:d6898. Published 2011 Nov 24. doi:10.1136/bmj.d6898

8. Fang M, Wang D, Coresh J, Selvin E. Trends in Diabetes Treatment and Control in U.S. Adults, 1999-2018. N Engl J Med. 2021;384(23):2219-2228. doi:10.1056/NEJMsa2032271

9. Emanuel EJ, Dellgren JL, McCoy MS, Persad G. Fair Allocation of GLP-1 and Dual GLP-1-GIP Receptor Agonists. N Engl J Med. 2024;390(20):1839-1842. doi:10.1056/NEJMp2400978

10. Hasbrouck L. Healthy People 2030: An Improved Framework. Health Educ Behav. 2021;48(2):113-114. doi:10.1177/1090198121997812

404   11.   Schmidt-Busby J, Wiles J, Exeter D, Kenealy T. Understanding 'context' in the self-
405   management of type 2 diabetes with comorbidities: A systematic review and realist
406   evaluation. Diabetes Res Clin Pract. 2018;142:321-334.
407   doi:10.1016/j.diabres.2018.06.003

408   12.   Ackermann RT, Holmes AM, Saha C. Designing a natural experiment to evaluate a
409   national health care-community partnership to prevent type 2 diabetes. Prev Chronic Dis.
410   2013;10:E12. doi:10.5888/pcd10.120149

411   13.   de Vries McClintock HF, Wiebe DJ, O'Donnell AJ, Morales KH, Small DS, Bogner HR.
412   Neighborhood social environment and patterns of adherence to oral hypoglycemic
413   agents among patients with type 2 diabetes mellitus. Fam Community Health.
414   2015;38(2):169-179. doi:10.1097/FCH.0000000000000069

415   14.   Laraia BA, Karter AJ, Warton EM, Schillinger D, Moffet HH, Adler N. Place matters:
416   neighborhood deprivation and cardiometabolic risk factors in the Diabetes Study of
417   Northern California (DISTANCE). Soc Sci Med. 2012;74(7):1082-1090.
418   doi:10.1016/j.socscimed.2011.11.036

419   15.   Shaha KC, Sultana S, Saha SK, Shahidullah SM, Jyoti BK. Patient Characteristics
420   Associated With Medication Adherence to Anti-Diabetic Drugs. Mymensingh Med J.
421   2019;28(2):423-428.

422   16.   McDoom MM, Cooper LA, Hsu YJ, Singh A, Perin J, Thornton RLJ. Neighborhood
423   Environment Characteristics and Control of Hypertension and Diabetes in a Primary
424   Care Patient Sample. J Gen Intern Med. 2020;35(4):1189-1198. doi:10.1007/s11606-
425   020-05671-y

426   17.   Myers CA, Slack T, Broyles ST, Heymsfield SB, Church TS, Martin CK. Diabetes
427   prevalence is associated with different community factors in the diabetes belt versus the
428   rest of the United States. Obesity (Silver Spring). 2017;25(2):452-459.
429   doi:10.1002/oby.21725

430   18.   Vijayaraghavan M, Jacobs EA, Seligman H, Fernandez A. The association between
431   housing instability, food insecurity, and diabetes self-efficacy in low-income adults. J
432   Health Care Poor Underserved. 2011;22(4):1279-1291. doi:10.1353/hpu.2011.0131

433   19.   Truong HP, Luke AA, Hammond G, Wadhera RK, Reidhead M, Joynt Maddox KE.
434   Utilization of Social Determinants of Health ICD-10 Z-Codes Among Hospitalized

435   Patients in the United States, 2016-2017. Med Care. 2020;58(12):1037-1043.

436   doi:10.1097/MLR.0000000000001418

437 20. Walker RJ, Strom Williams J, Egede LE. Influence of Race, Ethnicity and Social

438   Determinants of Health on Diabetes Outcomes. Am J Med Sci. 2016;351(4):366-373.

439   doi:10.1016/j.amjms.2016.01.008

440 21. Hill-Briggs F, Adler NE, Berkowitz SA, et al. Social Determinants of Health and Diabetes:

441   A Scientific Review. Diabetes Care. Published online November 2, 2020.

442   doi:10.2337/dci20-0053

443 22. Haire-Joshu D, Hill-Briggs F. The Next Generation of Diabetes Translation: A Path to

444   Health Equity. Annu Rev Public Health. 2019;40:391-410. doi:10.1146/annurev-

445   publhealth-040218-044158

446 23. Davidson J, Vashisht R, Butte AJ. From Genes to Geography, from Cells to Community,

447   from Biomolecules to Behaviors: The Importance of Social Determinants of Health.

448   Biomolecules. 2022;12(10):1449. Published 2022 Oct 9. doi:10.3390/biom12101449

449 24. Vashisht R, Patel A, Dahm L, et al. Second-Line Pharmaceutical Treatments for Patients

450   with Type 2 Diabetes [published correction appears in JAMA Netw Open. 2023 Nov

451   1;6(11):e2344113]. JAMA Netw Open. 2023;6(10):e2336613. Published 2023 Oct 2.

452   doi:10.1001/jamanetworkopen.2023.36613

453 25. Hripcsak G, Ryan PB, Duke JD, et al. Characterizing treatment pathways at scale using

454   the OHDSI network. Proc Natl Acad Sci U S A. 2016;113(27):7329-7336.

455   doi:10.1073/pnas.1510502113

456 26. Peterson TA, Fontil V, Koliwad SK, Patel A, Butte AJ. Quantifying Variation in Treatment

457   Utilization for Type 2 Diabetes Across Five Major University of California Health

458   Systems. Diabetes Care. 2021;44(4):908-914. doi:10.2337/dc20-0344

459 27. Singh GK. Area deprivation and widening inequalities in US mortality, 1969-1998. Am J

460   Public Health. 2003;93(7):1137-1143. doi:10.2105/ajph.93.7.1137

461 28. Nelson CA, Butte AJ, Baranzini SE. Integrating biomedical research and electronic

462   health records to create knowledge-based biologically meaningful machine-readable

463   embeddings. Nat Commun. 2019;10(1):3045. Published 2019 Jul 10.

464   doi:10.1038/s41467-019-11069-0

465   29.   Biedermann, P., Ong, R., Davydov, A. et al. Standardizing registry data to the OMOP

466   Common Data Model: experience from three pulmonary hypertension databases. BMC

467   Med Res Methodol 21, 238 (2021). https://doi.org/10.1186/s12874-021-01434-3

468   30.   Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of

469   Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS

470   Med. 2007;4(10):e297. doi:10.1371/journal.pmed.0040297

471   31.   Fairfield KM, Black AW, Ziller EC, et al. Area Deprivation Index and Rurality in Relation

472   to Lung Cancer Prevalence and Mortality in a Rural State. JNCI Cancer Spectr.

473   2020;4(4):pkaa011. Published 2020 Mar 7. doi:10.1093/jncics/pkaa011

474   32.   Ghirimoldi FM, Schmidt S, Simon RC, et al. Association of Socioeconomic Area

475   Deprivation Index with Hospital Readmissions After Colon and Rectal Surgery. J

476   Gastrointest Surg. 2021;25(3):795-808. doi:10.1007/s11605-020-04754-9

477   33.   Vince RA Jr, Jiang R, Bank M, et al. Evaluation of Social Determinants of Health and

478   Prostate Cancer Outcomes Among Black and White Patients: A Systematic Review and

479   Meta-analysis [published correction appears in JAMA Netw Open. 2023 Feb

480   1;6(2):e231256]. JAMA Netw Open. 2023;6(1):e2250416. Published 2023 Jan 3.

481   doi:10.1001/jamanetworkopen.2022.50416

482   34.   Hu J, Kind AJH, Nerenz D. Area Deprivation Index Predicts Readmission Risk at an

483   Urban Teaching Hospital. Am J Med Qual. 2018;33(5):493-501.

484   doi:10.1177/1062860617753063

485   35.   Luningham JM, Seth G, Saini G, et al. Association of Race and Area Deprivation With

486   Breast Cancer Survival Among Black and White Women in the State of Georgia. JAMA

487   Netw Open. 2022;5(10):e2238183. Published 2022 Oct 3.

488   doi:10.1001/jamanetworkopen.2022.38183

489   36.   Knighton AJ, Savitz L, Belnap T, Stephenson B, VanDerslice J. Introduction of an Area

490   Deprivation Index Measuring Patient Socioeconomic Status in an Integrated Health

491   System: Implications for Population Health. EGEMS (Wash DC). 2016;4(3):1238.

492   Published 2016 Aug 11. doi:10.13063/2327-9214.1238

493   37.   Kind AJH, Buckingham WR. Making Neighborhood-Disadvantage Metrics Accessible -

494   The Neighborhood Atlas. N Engl J Med. 2018;378(26):2456-2458.

495   doi:10.1056/NEJMp1802313

38. Agresti, A. (2002) Categorical Data Analysis, Second Edition. Hoboken, New Jersey:
John Wiley & Sons, Inc.
39. Harrell, F. E, (2001) Regression Modeling Strategies. New York: Springer-Verlag.
40. Kwak C, Clayton-Matthews A. Multinomial logistic regression. Nurs Res. 2002;51(6):404-
410. doi:10.1097/00006199-200211000-00009
41. Liang J, Bi G, Zhan C. Multinomial and ordinal Logistic regression analyses with multi-
categorical variables using R. Ann Transl Med. 2020;8(16):982. doi:10.21037/atm-2020-
57
42. Guevara, M., Chen, S., Thomas, S., Chaunzwa, T. L., Franco, I., Kann, B. H., Moningi,
S., Qian, J. M., Goldstein, M., Harper, S., Aerts, H. J. W. L., Catalano, P. J., Savova, G.
K., Mak, R. H., & Bitterman, D. S. (2024). Large language models to identify social
determinants of health in electronic health records. *NPJ digital medicine*, *7*(1), 6.
https://doi.org/10.1038/s41746-023-00970-0
43. DHHS. (2024). National Diabetes Statistics Report, 2024. National Diabetes Statistics
Report, 2

532 **Figure Legends:**

534 **Figure 1: Second-Line Treatment Cohort Design**

535 Flow chart illustrating cohort selection for patients being started on second-line sulfonylurea

536 (SU) across five academic health systems in University of California Health. A similar cohort

537 selection process was repeated for each of the other 3 categories of second-line treatments.

Figure 2: Second-line treatment options for Type 2 diabetes patients

Patients randomly selected from our cohort with varying characteristics (age, race, ethnicity, HbA1c, and insurance) are shown here. When each of these patients lives in an economically advantaged neighborhood (ADI 1, on the left) the model determines that they are most likely to receive a GLP-1RA as a second line treatment (percent indicates the model likelihood). When those same patients live in an economically disadvantaged neighborhood (ADI 10, on the right), they are most likely to receive a sulfonylurea.

548

549 **Figure 3: GPT-4 extraction and identification of Individual-Level SDOH Factors**

550 GPT-4 was provided with 522 clinical notes with Social History and SDOH sections and was

551 prompted to extract and identify individual-level SDOH factors from patients with a second-line

552 T2D treatment. Identified Individual-Level SDOH Factors for UCSF patients with 3a. Adverse

553 Housing 3b. Transportation, 3c. Relationship, 3d. patients with children, 3e. Employment, and

554 3f. Support stratified by their Drug Class.

555

556

557

558

559

560

561

562

563

Table 1: Baseline Characteristics of Type 2 Diabetes Patients with Second-Line

Treatments

Variable	No. (%) of patients					
	DPP4i (N=2918)	GLP-1RA (N=2736)	SGLT2i (N=2704)	Sulfonylurea (N=6732)	Total (N=15090)	P-Value
Age						
Mean (SD)	62.7 (13.4)	55.5 (13.7)	60.3 (13.4)	59.0 (12.9)	59.3 (13.4)	< 0.001
HbA1c						
Mean (SD)	8.59 (1.85)	8.83 (2.06)	8.62 (1.88)	9.19 (2.02)	8.91 (1.99)	< 0.001
Sex						
Female	1306 (44.8%)	1363 (49.8%)	996 (36.8%)	2870 (42.6%)	6535 (43.3%)	< 0.001
Male	1612 (55.2%)	1373 (50.2%)	1708 (63.2%)	3862 (57.4%)	8555 (56.7%)	
Race						
American Indian or Alaska Native	17 (0.6%)	22 (0.8%)	10 (0.4%)	34 (0.5%)	83 (0.6%)	< 0.001
Asian	550 (18.8%)	315 (11.5%)	498 (18.4%)	916 (13.6%)	2279 (15.1%)	
Black or African American	174 (6.0%)	238 (8.7%)	195 (7.2%)	539 (8.0%)	1146 (7.6%)	
Native Hawaiian or Other Pacific Islander	29 (1.0%)	20 (0.7%)	29 (1.1%)	81 (1.2%)	159 (1.1%)	
Other Race	560 (19.2%)	502 (18.3%)	480 (17.8%)	1535 (22.8%)	3077 (20.4%)	
Unknown	247 (8.5%)	332 (12.1%)	300 (11.1%)	430 (6.4%)	1309 (8.7%)	
White	1341 (46.0%)	1307 (47.8%)	1192 (44.1%)	3197 (47.5%)	7037 (46.6%)	
Ethnicity						
Hispanic or Latino	708 (24.3%)	794 (29.0%)	742 (27.4%)	2389 (35.5%)	4633 (30.7%)	< 0.001
Not Hispanic or Latino	1977 (67.8%)	1697 (62.0%)	1740 (64.3%)	3946 (58.6%)	9360 (62.0%)	
Unknown	233 (8.0%)	245 (9.0%)	222 (8.2%)	397 (5.9%)	1097 (7.3%)	
Area Deprivation Index (ADI)						
1	368 (12.6%)	308 (11.3%)	337 (12.5%)	519 (7.7%)	1532 (10.2%)	< 0.001
2	293 (10.0%)	262 (9.6%)	266 (9.8%)	551 (8.2%)	1372 (9.1%)	
3	323 (11.1%)	302 (11.0%)	298 (11.0%)	529 (7.9%)	1452 (9.6%)	
4	353 (12.1%)	360 (13.2%)	315 (11.6%)	771 (11.5%)	1799 (11.9%)	
5	317 (10.9%)	328 (12.0%)	336 (12.4%)	773 (11.5%)	1754 (11.6%)	

6	293 (10.0%)	336 (12.3%)	326 (12.1%)	947 (14.1%)	1902 (12.6%)	
7	295 (10.1%)	283 (10.3%)	250 (9.2%)	772 (11.5%)	1600 (10.6%)	
8	236 (8.1%)	245 (9.0%)	213 (7.9%)	676 (10.0%)	1370 (9.1%)	
9	231 (7.9%)	176 (6.4%)	208 (7.7%)	659 (9.8%)	1274 (8.4%)	
10	209 (7.2%)	136 (5.0%)	155 (5.7%)	535 (7.9%)	1035 (6.9%)	
Primary Insurance						
Medicaid	700 (24.0%)	607 (22.2%)	720 (26.6%)	2515 (37.4%)	4542 (30.1%)	< 0.001
Medicare	880 (30.2%)	495 (18.1%)	634 (23.4%)	1762 (26.2%)	3771 (25.0%)	
Private	1273 (43.6%)	1580 (57.7%)	1301 (48.1%)	2349 (34.9%)	6503 (43.1%)	
Veterans Affairs	65 (2.2%)	54 (2.0%)	49 (1.8%)	106 (1.6%)	274 (1.8%)	

567 Baseline Characteristics of type 2 diabetes patients with second-line treatment initiation

568 between January 2012 - November 2023. *Percentages within each ADI variable group add up

569 to 100% in each column.

595 **Table 2: Results of the Multinomial Regression Model**

Variable	DPP4i		GLP-1RA		SGLT2i	
	OR (95% CI)	P value	OR (95% CI)	P value	OR (95% CI)	P value
Area Deprivation Index (ADI)	0.96 (0.95-0.98)	< 0.001	0.94 (0.92-0.96)	< 0.001	0.95 (0.93-0.97)	< 0.001
HbA1c	0.90 (0.88-0.92)	< 0.001	0.90 (0.87-0.92)	< 0.001	0.88 (0.85-0.90)	< 0.001
Age	1.02 (1.01-1.02)	< 0.001	0.98 (0.97-0.98)	< 0.001	1.01 (1.00-1.01)	0.001
Sex						
Female	1.10 (1.00-1.20)	0.043	1.44 (1.31-1.58)	< 0.001	0.79 (0.72-0.86)	< 0.001
Race						
American Indian or Alaska Native	1.33 (0.74-2.41)	0.345	1.52 (0.87-2.64)	0.138	0.85 (0.42-1.74)	0.662
Asian	1.19 (1.05-1.35)	0.008	0.62 (0.53-0.72)	< 0.001	1.25 (1.09-1.43)	0.001
Black or African American	0.81 (0.67-0.98)	0.031	1.03 (0.86-1.22)	0.759	1.06 (0.88-1.27)	0.533
Native Hawaiian or Other Pacific Islander	0.86 (0.56-1.33)	0.507	0.53 (0.32-0.87)	0.012	1.01 (0.65-1.56)	0.969
Other Race	1.21 (1.06-1.38)	0.004	1.04 (0.91-1.19)	0.552	1.04 (0.90-1.19)	0.604
Unknown	1.35 (1.10-1.65)	0.004	1.54 (1.27-1.86)	< 0.001	1.81 (1.49-2.20)	< 0.001
Ethnicity						
Hispanic or Latino	0.73 (0.64-0.83)	< 0.001	0.78 (0.69-0.88)	< 0.001	0.90 (0.79-1.02)	0.104
Unknown	1.02 (0.83-1.25)	0.859	0.92 (0.75-1.14)	0.459	0.90 (0.73-1.12)	0.346
Primary Insurance						
Medicare	1.19 (1.05-1.36)	0.007	1.30 (1.12-1.51)	< 0.001	0.93 (0.81-1.07)	0.297
Private Health Insurance	1.67 (1.49-1.87)	< 0.001	2.39 (2.13-2.69)	< 0.001	1.56 (1.40-1.75)	< 0.001
Veterans Affairs	1.62 (1.17-2.24)	0.004	2.26 (1.60-3.21)	< 0.001	1.29 (0.91-1.84)	0.158

597 Odds Ratio table of patients receiving second-line treatment across patient characteristics with

598 SU as the reference. An OR = 1 indicates no difference between SU and other drugs, OR > 1

599 indicates increased likelihood of other treatments being used as a second line therapeutic

600 compared with SU and OR < 1 indicates decreased likelihood of other treatments compared

601 with SU.